½ÌѧÎÄ¿âÍø - ȨÍþÎĵµ·ÖÏíÔÆÆ½Ì¨
ÄúµÄµ±Ç°Î»ÖãºÊ×Ò³ > ·¶ÎÄ´óÈ« > ÎÄÃØ×ÊÁÏ >

Õó·¢ÐÔ·¿²ü²ÉÓÃÒ©ÎïÖÎÁƵÄÁÙ´²»¤ÀíÅäºÏ(2)

À´Ô´£ºÍøÂçÊÕ¼¯ ʱ¼ä£º2026-04-23
µ¼¶Á£º ÐÄÀíÒòËØÊÇÓ°ÏìÖÎÁƵÄÖ±½ÓÒòËØ£¬ Òò´Ë£¬ ÔÚ»¤Àí¹ý³ÌÖгýÒªÕë¶Ô¼²² ¢Éú»îµÈ·½Ãæ½øÐйÜÀí£¬ »¹ÒªÕë¶Ô»¼ÕßÐÄÀíÒòËØ½øÐйÜÀí£¬ ʹ»¼Õß±£³ÖƽÎÈÇéÐ÷£¬ ÌáÉýÖÎÁÆÒÀ´ÓÐÔ[16-18].³£¹æ»¤Àí¸ÉÔ¤½ö¶Ô»¼Õß²¡Çé½øÐйÜÀí£¬ δ¶Ô»¼

¡¡¡¡

¡¡¡¡ÐÄÀíÒòËØÊÇÓ°ÏìÖÎÁƵÄÖ±½ÓÒòËØ£¬ Òò´Ë£¬ ÔÚ»¤Àí¹ý³ÌÖгýÒªÕë¶Ô¼²²¡¡¢Éú»îµÈ·½Ãæ½øÐйÜÀí£¬ »¹ÒªÕë¶Ô»¼ÕßÐÄÀíÒòËØ½øÐйÜÀí£¬ ʹ»¼Õß±£³ÖƽÎÈÇéÐ÷£¬ ÌáÉýÖÎÁÆÒÀ´ÓÐÔ[16-18].³£¹æ»¤Àí¸ÉÔ¤½ö¶Ô»¼Õß²¡Çé½øÐйÜÀí£¬ δ¶Ô»¼ÕßÉúÀí¡¢ÐÄÀí½øÐйÜÀí£¬ Òò´Ë¹ÜÀíЧ¹ûÒÔ¼°ÖÎÁÆÐ§¹û²»¹»ÀíÏë¡£×ۺϻ¤Àí¸ÉÔ¤×÷ΪһÖÖÐÂÐÍ»¤Àíģʽ£¬ ²»½öÄÜÕë¶Ô»¼Õß²¡Çé½øÐйÜÀí£¬ »¹ÄÜÕë¶Ô»¼ÕßÉú»î¡¢ÐÄÀíÇéÐ÷½øÐйÜÀí£¬ ´Ó¶øÈ«Ãæ¸ÄÉÆ»¼Õß×´¿ö£¬ ´ïµ½¸üÀíÏëµÄ¸ÉԤЧ¹û[19-21].

¡¡¡¡

¡¡¡¡±¾Ñо¿½á¹ûÏÔʾ£¬ ¹Û²ì×黼ÕßÁÆÐ§ÆÀ¹ÀÓÐЧÂÊΪ90.0%, ¸ßÓÚ¶ÔÕÕ×é £¨P<0.05£© , ¼´¹Û²ì×黼Õß¾­×ۺϻ¤Àíºó£¬ ÖÎÁÆÐ§¹ûÏÔןÃÓÚ¶ÔÕÕ×飬 ͬʱ¹Û²ì×黼ÕßÉúÃüÖÊÁ¿ÆÀ·ÖΪ £¨85.2±5.6£© ·Ö£¬ ¸ßÓÚ¶ÔÕÕ×é £¨P<0.05£© .´ËÍ⣬ ¹Û²ì×黼Õß»¤ÀíÂúÒâ¶ÈÏÔןßÓÚ¶ÔÕÕ×é £¨P<0.05£© , ½øÒ»²½Ö¤Ã÷×ۺϻ¤Àí¸ÉÔ¤Ó¦ÓÃÔÚÕó·¢ÐÔ·¿²ü»¼ÕßÖÐЧ¹ûÀíÏë¡£

¡¡¡¡

¡¡¡¡×ÛÉÏËùÊö£¬ ×ÛºÏÐÔ»¤Àí¸ÉÔ¤Äܹ»¸ÄÉÆÕó·¢ÐÔ·¿²ü»¼ÕßµÄÖÎÁÆÐ§¹û£¬ ÌáÉýÉúÃüÖÊÁ¿£¬ ½µµÍ¾À·×·¢ÉúÂÊ£¬ ¾ßÓнϸߵÄÖÎÁƼÛÖµ£¬ ÖµµÃÍÆ¹ãÓ¦Óá£

¡¡¡¡

¡¡¡¡²Î¿¼ÎÄÏ×

¡¡¡¡

¡¡¡¡[1]ÍõÓñÈ磬 ÖÜÑ࣬ ºúÓñ·¼£¬ µÈ¡£¾­Æ¤Àä¶³ÇòÄÒµ¼¹ÜÏûÈÚÖÎÁÆÕó·¢ÐÔÐÄ·¿²ü¶¯»¼ÕßµÄÊõÖл¤Àí[J].»¤ÀíѧÔÓÖ¾£¬ 2014, 29 £¨21£© :27-29.

¡¡¡¡[2]ÁºÁ¬»Ô¡£»¤Àí¸ÉÔ¤¶ÔÕó·¢ÐÔÐÄ·¿²ü¶¯»¼ÕßÒ©ÎïÖÎÁÆÒÀ´ÓÐÔ¼°Ð§¹ûµÄÓ°Ïì[J].¹ú¼Ê»¤ÀíѧÔÓÖ¾£¬ 2013, 34 £¨7£© :944-947.

¡¡¡¡[3]Balt J C, Karadavut S, Mulder A A, et al.Conduction recovery in patients with recurrent atrial fibrillation after pulmonary vein isolation using multi-electrode duty cycled radiofrequency ablation[J].J Interv Card Electrophysiol, 2013, 37 £¨9£© :197-204.¡¡¡¡

¡¡¡¡[4]ÕÅÆ½£¬ 꽨¾ü£¬ ³ÂÃÀºì£¬ µÈ¡£Ì½ÌÖ°·µâͪÖÎÁƼ±ÐÔÐ£ËÀ°é·¿²üµÄÁÙ´²»¤Àí¶Ô²ß[J].ÊÀ½ç×îÐÂҽѧÐÅÏ¢ÎÄÕª£¬ 2015, 15 £¨90£© :226-226.¡¡¡¡

¡¡¡¡[5]Aytemir K, Oto A, Canpolat U, et al.Immediate and medium-term outcomes of cryoballoon-based pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation:single-centre experience[J].J Interv Card Electrophysiol, 2013, 38 £¨3£© :187-195.¡¡¡¡

¡¡¡¡[6]January CT, Wann LS, Alpert JS, et al.2014 AHA/ACC/HRS Guideline for the Managementof Patients With Atrial Fibrillation:A Report of the American College of C ardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J].J Am Coll Cardiol, 2014, 64 £¨21£© :e1-76.¡¡¡¡

¡¡¡¡[7]Ëï»·£¬ ÀîÀö£¬ ³ÂÑǾ꣬ µÈ¡£»¤Àí¸ÉÔ¤¶ÔÕó·¢ÐÔÐÄ·¿²ü¶¯»¼ÕßÒ©ÎïÖÎÁÆÒÀ´ÓÐÔ¼°Ð§¹ûµÄÓ°Ïì[J].ÖйúÎÀÉú±ê×¼¹ÜÀí£¬ 2015, 6 £¨30£© :230-231.¡¡¡¡

¡¡¡¡[8]ÂÀά¾ê£¬ Íò¾©Ã·£¬ Íõ»Ý¡£Õó·¢ÐÔÐÄ·¿²ü¶¯»¼Õß½éÈëÖÎÁƵÄÐÄÀí»¤Àí[J].ºÚÁú½­Ò½Ò©¿ÆÑ§£¬ 2013, 36 £¨1£© :88-88.¡¡¡¡

¡¡¡¡[9]Montserrat S, Gabrielli L, Borras R, et al.Left atrial size and function by three-dimensional echocardiography to predict arrhythmia recurrence after first and repeated ablation of atrial fibrillation[J].Eur Heart J Cardiovasc Imaging, 2014, 15 £¨5£© :515-522.¡¡¡¡

¡¡¡¡[10]ÕÅÓ¢£¬ ÒüÊ¿ÄС£°·µâͪÁªºÏ¶ò±´É³Ì¹ÖÎÁƸßѪѹ²¡ºÏ²¢Õó·¢ÐÔ·¿²üµÄÁÙ´²ÁÆÐ§¹Û²ì[J].ÖÐÎ÷Ò½½áºÏÐÄÄÔѪ¹Ü²¡ÔÓÖ¾£¬ 2015, 13 £¨4£© :534-535.¡¡¡¡

¡¡¡¡[11]Nyrnes A, Toft I, Njlstad I, et al.Uric acid is associated with future atrial fibrillation:an 11-year follow-up of 6308men and women-the Tromso Study[J].Europace, 2014, 16 £¨3£© :320-326.

¡­¡­ ´Ë´¦Òþ²Ø£º351×Ö£¬È«²¿ÎĵµÄÚÈÝÇëÏÂÔØºó²é¿´¡£Ï²»¶¾ÍÏÂÔØ°É ¡­¡­
Õó·¢ÐÔ·¿²ü²ÉÓÃÒ©ÎïÖÎÁƵÄÁÙ´²»¤ÀíÅäºÏ(2).doc ½«±¾ÎĵÄWordÎĵµÏÂÔØµ½µçÄÔ£¬·½±ã¸´ÖÆ¡¢±à¼­¡¢ÊղغʹòÓ¡
±¾ÎÄÁ´½Ó£ºhttps://www.jiaowen.net/fanwen/4053.html£¨×ªÔØÇë×¢Ã÷ÎÄÕÂÀ´Ô´£©
Copyright © 2020-2025 ½ÌÎÄÍø °æÈ¨ËùÓÐ
ÉùÃ÷ :±¾ÍøÕ¾×ðÖØ²¢±£»¤ÖªÊ¶²úȨ£¬¸ù¾Ý¡¶ÐÅÏ¢ÍøÂç´«²¥È¨±£»¤ÌõÀý¡·£¬Èç¹ûÎÒÃÇ×ªÔØµÄ×÷Æ·ÇÖ·¸ÁËÄúµÄȨÀû,ÇëÔÚÒ»¸öÔÂÄÚ֪ͨÎÒÃÇ£¬ÎÒÃǻἰʱɾ³ý¡£
¿Í·þQQ£º78024566 ÓÊÏ䣺78024566@qq.com
ËÕICP±¸19068818ºÅ-2
Top
¡Á ÓοͿì½ÝÏÂÔØÍ¨µÀ£¨ÏÂÔØºó¿ÉÒÔ×ÔÓɸ´ÖƺÍÅŰ棩
VIP°üÔÂÏÂÔØ
ÌØ¼Û£º29 Ôª/Ô ԭ¼Û:99Ôª
µÍÖÁ 0.3 Ôª/·Ý ÿÔÂÏÂÔØ150·Ý
ȫվÄÚÈÝÃâ·Ñ×ÔÓɸ´ÖÆ
VIP°üÔÂÏÂÔØ
ÌØ¼Û£º29 Ôª/Ô ԭ¼Û:99Ôª
µÍÖÁ 0.3 Ôª/·Ý ÿÔÂÏÂÔØ150·Ý
ȫվÄÚÈÝÃâ·Ñ×ÔÓɸ´ÖÆ
×¢£ºÏÂÔØÎĵµÓпÉÄܳöÏÖÎÞ·¨ÏÂÔØ»òÄÚÈÝÓÐÎÊÌ⣬ÇëÁªÏµ¿Í·þЭÖúÄú´¦Àí¡£
¡Á ³£¼ûÎÊÌ⣨¿Í·þʱ¼ä£ºÖÜÒ»µ½ÖÜÎå 9:30-18:00£©